The quality of life of millions depends on the availability of our medicines, as Egis sells the most boxes of medicine in Hungary. Hungarian doctors most often choose Egis medicines particularly for the therapy of cardiovascular diseases, which is a common disease. Our medicines provide therapeutic solutions for the diseases cardiovascular diseases (38%), for the illnesses of the central nervous system (17%) and respiratory system (10%), further 10% are cancer treatment and immunotherapeutic drugs. Taking these medicines continuously is essential for maintaining the patients’ quality of life and for the success of the therapy.

WHO has created a six-step protocol: by applying this method, we can remove the germs, viruses, and bacteria from the surface of our hands.

The semester-long accredited credit course “Egis Pharma from A to Z” has started for the fourth time already.

The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.

The pharmaceutical industry plays a key role in the Hungarian economy’s change of dimension.

To support the CSR activities of local companies, the Hungarian Business Responsibility founded its special awards, called CSR Hungary. This year, Egis was awarded in the ‘Inner CSR Solutions’ category that comes with a two-year trademark right.

Microsoft and HR Fest — the largest HR professional festival in Hungary — established a new professional award category within HR Best awards called ‘Future Proof Organizations’.

One of Egis’ core values is care – with our immediate surroundings as well as in a wider sense. As a responsible company, we strive to support such projects that serve people’s safety and comfort. In this spirit, Egis decided to support the construction of a safe bicycle railroad crossing that is used also by many of our employees daily on their way to our Körmend plant.

Egis and our consortia partners have won 2,332 billion HUF direct grant in the framework of the innovation tender GINOP-2.2.1-15-2016-00023 for the realisation of the above-mentioned project.

Egis Pharmaceutical PLC’s Senior pharmaceutical sales rep participated very successfully at Medigames. Having won two gold medals, four silvers, and three bronze, pharmacist Dr. Judit Karagics contributed considerably to the 3rd place Hungary reached in the medal table. This excellent performance strengthens Egis’ reputation in the international target groups.

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.

Egis Russia’s Buy for Good campaign that was carried out in 2018 won the award of ‘Best Social Projects in Russia’ in the category of medical and social projects.